Q1 2025 · 13F-HR
REGENERON PHARMACEUTICALS, INC. (REGN)holdings as filed
Filed 2025-05-02 · accession 0001104659-25-044118
$1.23B
Reported value
6
Positions
2025-03-31
Period end
The Brief · REGENERON PHARMACEUTICALS, INC. (REGN) · Q1 2025
AI · grounded in 13F
REGENERON PHARMACEUTICALS, INC. (REGN) reported no changes to its 13F holdings for 2025-03-31 relative to 2024-12-31.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 02043Q107 | ALNY | Alnylam Pharmaceuticals, Inc. | $1.20B | 97.2% | 4,444,445 | Common | SOLE |
| 45826J105 | NTLA | Intellia Therapeutics, Inc. | $26.3M | 2.13% | 3,702,995 | Common | SOLE |
| 901384107 | TSVT* | 2seventy Bio, Inc. | $6.2M | 0.50% | 1,254,827 | Common | SOLE |
| 00773U207 | AVU0 | Adverum Biotechnologies, Inc. | $790,572 | 0.06% | 180,909 | Common | SOLE |
| 007002108 | TORCEUR | Adicet Bio, Inc. | $730,978 | 0.06% | 968,183 | Common | SOLE |
| 09609G209 | BLE0 | Bluebird Bio, Inc. | $102,480 | 0.01% | 21,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.